Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 05, 2015 4:41 AM ET

Life Sciences Tools and Services

Company Overview of Progenitor Cell Therapy, LLC

Company Overview

Progenitor Cell Therapy, LLC provides contract development and manufacturing services for cell therapy products. The company offers manufacturing solutions; engineering and innovation services; product and process development services; cell and tissue processing; storage, distribution, and delivery of tissues, primary cells, and cell therapy products; and consulting and regulatory support services, such as product and process development, GTP/cGMP manufacturing, regulatory services, and business development and commercialization. It serves academic, biotech, pharmaceutical, and professional clients in the United States. The company was founded in 1997 and is based in Allendale, New Jersey. I...

4 Pearl Court

Suite C

Allendale, NJ 07401

United States

Founded in 1997

Phone:

201-883-5300

Fax:

201-883-1409

Key Executives for Progenitor Cell Therapy, LLC

President, Chief Scientific Officer and Member of Board Manager
Age: 58
Chief Medical Officer
Age: 58
Senior Vice President of Investor Relations
Director of Human Resources
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Progenitor Cell Therapy, LLC Key Developments

ImmunoCellular Therapeutics Selects PCT, LLC to Manufacture ICT-107 Immunotherapy for Glioblastoma

Caladrius Biosciences (CLBS) announced that its subsidiary, PCT, LLC, has been selected by ImmunoCellular Therapeutics (IMUC) as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.

ImmunoCellular Therapeutics Enters into Manufacturing Agreement with Pct LLC for US Production of ICT-107 for Phase 3 Registration Trial

ImmunoCellular Therapeutics Ltd. announced the selection of PCT, LLC as the US manufacturer for ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. Under the terms of the multi-year agreement, PCT will provide current good manufacturing practice (cGMP) services for the manufacture of clinical supplies of ICT-107, a dendritic cell-based immunotherapy targeting six tumor-associated antigens.

Progenitor Cell Therapy Announces Executive Changes

NeoStem Inc. announced the addition of three experienced leaders in the biotech industry to its management team. Harry Lam, Ph.D., Ann M. Daus, Ph.D., and Anna Crivici, Ph.D. bring a breadth of experience in leading high performing teams to meet operational goals. Harry Lam, Ph.D. joins NeoStem's subsidiary, Progenitor Cell Therapy (PCT), as Vice President, Manufacturing and Technical Operations, where he will be responsible for overseeing manufacturing operations, engineering, technology transfer, facilities, manufacturing development, and process development. An experienced technical leader, Dr. Lam has over thirty years of biopharmaceutical manufacturing experience. Prior to joining PCT, he spent seventeen years at Genentech, where his advanced degrees in Chemical Engineering allowed him to advance to the position of Roche Global Head of Contract Manufacturing Operations, Commercial Drug Substance. Recently, he was Senior Vice President, Technical Operations, at KaloBios Pharmaceuticals, and Vice President and Head of Manufacturing for Shire Regenerative Medicine. Ann M. Daus, Ph.D. joins PCT as Vice President, Quality, where she will be responsible for establishing and managing all aspects of Quality as related to the regulated (cGMP/GTP) manufacturing of both clinical and commercial cell therapy products including company-wide quality plans and corporate audit programs with participation in regulatory strategies/submissions. An experienced leader with over twenty years of management experience, Dr. Daus brings to PCT a successful track record for effective performance and leadership in the fields of biopharmaceuticals, pharmaceuticals, medical devices, OTC, diagnostics, aseptic filling, blood banking and contract manufacturing. Previously, Dr. Daus served as Vice President, Quality at Laureate Biopharma, and has held various leadership positions at ImClone Systems Incorporated, Smith-Kline Beecham Pharmaceuticals (SKB) and Johnson & Johnson.

Similar Private Companies By Industry

Company Name Region
Abgent, Inc. United States
Jon E. Block, Ph.D., Incorporated United States
BioLife Plasma Services L.P. United States
Vince & Associates Clinical Research Inc. United States
MedTrials Incorporated United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Progenitor Cell Therapy, LLC, please visit pctcelltherapy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.